Top

Published in:

01-12-2021 | Severe Acute Respiratory Syndrome Coronavirus | Review

SARS-CoV-2 pneumonia—receptor binding and lung immunopathology: a narrative review

Authors: Maria Clara Saad Menezes, Diego Vinicius Santinelli Pestana, Gustavo Rosa Gameiro, Luiz Fernando Ferraz da Silva, Ėlodie Baron, Jean-Jacques Rouby, José Otavio Costa Auler Jr

Published in: Critical Care | Issue 1/2021

Abstract

The current pandemic of COVID-19 caused thousands of deaths and healthcare professionals struggle to properly manage infected patients. This review summarizes information about SARS-CoV-2 receptor binding dynamics and intricacies, lung autopsy findings, immune response patterns, evidence-based explanations for the immune response, and COVID-19-associated hypercoagulability.

Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.CrossRefPubMedPubMedCentral

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.PubMedPubMedCentralCrossRef

Yuntao W, Wenzhe H, Yaowei H, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020 21–27 March; 395(10228): 949–950

Gattinoni L, Chiumello D, Cairon P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099–102.PubMedPubMedCentralCrossRef

Xu L, Xiaochun M. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care. 2020;24:198.CrossRef

Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24:154. https://doi.org/10.1186/s13054-020-02880-z.CrossRefPubMedPubMedCentral

Mauri T, Spinelli E, Scotti E, et al. Potential for lung recruitment and ventilation-perfusion mismatch in patients with the acute respiratory distress syndrome from coronavirus disease 2019. Crit Care Med. 2020;48(8):1129–34. https://doi.org/10.1097/CCM.0000000000004386.CrossRefPubMedPubMedCentral

Salvatore G, Mirabella L, Murgolo F, et al. Effects of positive end-expiratory pressure in “High Compliance” Severe Acute Respiratory Syndrome Coronavirus 2 Acute Respiratory Distress Syndrome, Critical Care Medicine: September 15, 2020—Volume Online First - Issue - doi: https://doi.org/10.1097/CCM.0000000000004640

Gao GF. From “A”IV to “Z”IKV: attacks from emerging and re-emerging pathogens. Cell. 2018;172:1157–9.PubMedPubMedCentralCrossRef

10.

Richman D, Whitley R, Hayden F. Clinical virology. 4th ed. Washington: ASM Press; 2016.CrossRef

11.

Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. JAMA. 2020;323:707–8.PubMedCrossRef

12.

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.CrossRefPubMed

13.

Wong G, Liu W, Liu Y, et al. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18:398–401.PubMedPubMedCentralCrossRef

14.

Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–39.PubMedPubMedCentralCrossRef

15.

Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 180:934–3.

16.

Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383:45–51.PubMedPubMedCentralCrossRef

17.

Dobbs LG. Pulmonary surfactant. Anna Rev Med. 1989;40:431–46.CrossRef

18.

Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012. https://doi.org/10.1155/2012/307315.CrossRefPubMed

19.

Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.PubMedPubMedCentralCrossRef

20.

Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.CrossRefPubMedPubMedCentral

21.

Walls A, Park Y, Tortorici M, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281.PubMedPubMedCentralCrossRef

22.

Wrapp D, Wang N, Corbett K, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3.PubMedPubMedCentralCrossRef

23.

Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658–64.PubMedPubMedCentralCrossRef

24.

Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85:873–82.PubMedCrossRef

25.

Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742.PubMedPubMedCentralCrossRef

26.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.PubMedPubMedCentralCrossRef

27.

Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–13.PubMedPubMedCentralCrossRef

28.

Fox S, Akmatbekov A, Harbert L, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans, . Lancet Respir Med. 2020;8:682.CrossRef

29.

Ackermann M, Verleden S, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. NEJM. 2020;383:122–4.CrossRef

30.

Rouby JJ, Martin De Lassale E, Poete P et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis. 1992;146:1059–66

31.

Barton L, Duval E, Stroberg E, et al. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Path. 2020;153:725–33.PubMedCrossRef

32.

Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517–1519. doi: https://doi.org/10.1111/jth.14844.

33.

Monteiro RPA, Oliveira EP, Saldiva PHN, Dolhnikoff M. Duarte‐Neto AN; Brazilian Image Autopsy Study Group. Histological‐ultrasonographical correlation of pulmonary involvement in severe COVID‐19. Intensive Care Med. 2020; 46:1766–8. doi: https://doi.org/10.1007/s00134-020-06125-z.

34.

Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, et al. Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology. 2020. https://doi.org/10.1111/his.14160.CrossRefPubMedCentral

35.

Menter T, Haslbauer JD, Nienhold R, et al. A post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. https://doi.org/10.1111/his.14134.CrossRefPubMedPubMedCentral

36.

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.PubMedPubMedCentralCrossRef

37.

Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–4.PubMedPubMedCentralCrossRef

38.

Martines RB, Ritter JM, Matkovic E, et al.: COVID-19 Pathology Working Group. Pathology and Pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis. 2020; 26(9). doi: https://doi.org/10.3201/eid2609.20209

39.

Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 2000;21:455.CrossRef

40.

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.PubMedPubMedCentralCrossRef

41.

Goldsmith CS, Miller SE, Martines RB, et al. Electron microscopy of SARS-CoV-2: a challenging task. Lancet. 2020;395(10238):e99. https://doi.org/10.1016/S0140-6736(20)31188-0.CrossRefPubMedPubMedCentral

42.

Miller SE, Brealey JK. Visualization of putative coronavirus in kidney. Kidney Int. 2020;98:231–2.PubMedPubMedCentralCrossRef

43.

Zhang H, Zhou P, Wei Y, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Inter Med. 2020;172:629–32.CrossRef

44.

Su H, Yang M, Wan C, Yi LX, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–27.PubMedPubMedCentralCrossRef

45.

Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202:415–24.PubMedPubMedCentralCrossRef

46.

Kerget B, Kerget F, Koçak AO, Kızıltunç A, Araz Ö, Uçar EY, et al. Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung. 2020;777–84.

47.

Mrozek S, Jabaudon M, Jaber S, Paugam-Burtz C, Lefrant J-Y, Rouby J-J, et al. Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study. Chest. 2016;150:998–1007.PubMedCrossRef

48.

Constantin JM, Jabaudon M, Lefrant JY, Jaber S, Quenot JP, Langeron O, et al.; AZUREA Network. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med. 2019 Oct;7(10):870–80.

49.

Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;611–20.

50.

Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, et al. Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients. J Infect Dis. 2020;894–8.

51.

Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in china. NEJM. 2020;382:1708–20.PubMedCrossRef

52.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395:497–506.PubMedPubMedCentralCrossRef

53.

Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020. https://doi.org/10.1016/j.ebiom.2020.102763.CrossRefPubMedPubMedCentral

54.

Cowland J, Borregaard N. Granulopoiesis and granules of human neutrophils. Immunol Rev. 2016;273:11–28.PubMedCrossRef

55.

Adrover J, Aroca-Crevillen A, Crainiciuc G, et al. Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation. Nat Immunol. 2020;21:135–44.PubMedPubMedCentralCrossRef

56.

McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202:812–21.PubMedPubMedCentralCrossRef

57.

Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007. https://doi.org/10.1002/eji.200737772.CrossRefPubMedPubMedCentral

58.

Liu Q, Zhou Y, Yang Z. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;3:3–10.CrossRef

59.

Chousterman B, Swirski F, Weber G. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517–28.CrossRefPubMed

60.

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.PubMedPubMedCentralCrossRef

61.

Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8.PubMedCrossRef

62.

Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: a brief look at potential therapeutic tactics. Life Sci. 2020;257:118097. https://doi.org/10.1016/j.lfs.2020.118097.CrossRefPubMedPubMedCentral

63.

Liu T, Zhang J, Yang Y, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020;12(7):e12421.PubMedCrossRefPubMedCentral

64.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.PubMedPubMedCentralCrossRef

65.

Li T, Lu L, Zhang W, et al. Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. Arch Gerontol Geriatr. 2020;15(91):104185. https://doi.org/10.1016/j.archger.2020.104185.CrossRef

66.

Boregowda U, Perisetti A, Nanjappa A et al. Addition of tocilizumab to the standard of care reduces mortality in Severe COVID-19: a systematic review and meta-analysis. Front Med (Lausanne) .2020;7:586221. https://doi.org/10.3389/fmed.2020.586221.

67.

Salvarani C, Dolci G, Massari M, et al. RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized With COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020;20:e206615.

68.

Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011. https://doi.org/10.1016/j.bbamcr.2011.01.034.CrossRefPubMed

69.

Mehta P, McAuley DF, Brown M, et al. HLH Across Speciality Collaboration, UK COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.PubMedPubMedCentralCrossRef

70.

Arico M, Danesino C, Pende D, et al. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001;114:761–9.PubMedCrossRef

71.

Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transpl. 2010. https://doi.org/10.1016/j.bbmt.2009.11.014.

72.

Sinha P, Matthay M, Calfee C.: Is a “Cytokine Storm” Relevant to COVID-19? JAMA Intern Med. Published online June 30, 2020. doi:https://doi.org/10.1001/jamainternmed.2020.3313

73.

Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189:428–37.PubMedPubMedCentralCrossRef

74.

Mahmudpour M, Roozbeh J, Keshavarz M, et al. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133:155151.PubMedPubMedCentralCrossRef

75.

Peteranderl C, Herold S. The impact of the interferon/TNF-related apoptosis-inducing ligand signaling axis on disease progression in respiratory viral infection and beyond. Front Immunol. 2017;8:313.PubMedPubMedCentral

76.

Iwasaki A, Pillai P. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315–28.PubMedPubMedCentralCrossRef

77.

Teijaro J, Walsh K, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146:980–9.PubMedPubMedCentralCrossRef

78.

Hui L, Liang L, Dingyu Z, Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20.CrossRef

79.

RECOVERY Collaborative Group, Horby P, Lim WS, et al.: Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020; doi: https://doi.org/10.1056/NEJMoa2021436.

80.

Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–76.CrossRefPubMed

81.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.PubMedCrossRefPubMedCentral

82.

Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020. https://doi.org/10.1177/1358863X20932640.CrossRefPubMedPubMedCentral

83.

Iba T, Levy J, Levi M, et al. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020. https://doi.org/10.1097/CCM.0000000000004458.CrossRefPubMedPubMedCentral

84.

Jose R, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30216-2.CrossRefPubMedPubMedCentral

85.

Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;S0735–1097(20):35218–9.

86.

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–6.PubMedCrossRef

87.

Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020; S0735-1097(20): 35008-7.

Title: SARS-CoV-2 pneumonia—receptor binding and lung immunopathology: a narrative review
Authors: Maria Clara Saad Menezes
Diego Vinicius Santinelli Pestana
Gustavo Rosa Gameiro
Luiz Fernando Ferraz da Silva
Ėlodie Baron
Jean-Jacques Rouby
José Otavio Costa Auler Jr
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
Pneumonia
Acute Respiratory Distress-Syndrome
COVID-19
Pathology
Cytokines
Published in: Critical Care / Issue 1/2021
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-020-03399-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

SARS-CoV-2 pneumonia—receptor binding and lung immunopathology: a narrative review

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Renin–angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report

Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: do not confound access route and specific drug complications!

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study

Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury

The Dutch Data Warehouse, a multicenter and full-admission electronic health records database for critically ill COVID-19 patients